Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis

BACKGROUND: Androgen-deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor-targeted agents (ARTA) or docetaxel with ADT significantly improved clinical outcomes in this setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiorano, B.A., De Giorgi, U., Roviello, G., Messina, C., Altavilla, A., Cattrini, C., Mennitto, A., Maiello, E., Di Maio, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588886/
https://www.ncbi.nlm.nih.gov/pubmed/36152486
http://dx.doi.org/10.1016/j.esmoop.2022.100575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588886/
https://www.ncbi.nlm.nih.gov/pubmed/36152486
http://dx.doi.org/10.1016/j.esmoop.2022.100575

Ejemplares similares